CompletedNot Applicable

EndoTic - Endothelium and Ticagrelor

Spain109 participantsStarted 2015-03

Plain-language summary

Randomized clinical trial to assess the influence of treatment with ticagrelor or clopidogrel in the number of CECs (Circulating Endothelial Cells) and EPCs (Endothelial Progenitor Cells) in patients with ACS (Acute Coronary Syndrome), from baseline levels to chronic levels (1 month).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Willing to sign Informed Consent Form * 18 yr or older * Male and female (post menopause or contraception treatment) * ACS diagnosed with elevation of myocardial infarction biomarkers (as of 3rd Universal Definition of MI) * Planned invasive strategy (coronariography performed within 72hrs after admission) Exclusion Criteria: * Aspirin, clopidogrel or ticagrelor allergy. * Hemorrhagic diathesis or very high risk of bleeding. * Current treatment with oral anticoagulants, thienopyridines or ticagrelor. * Limited life expectancy. * Elective surgery planned. * High chance of not being able to complete the follow-up period.

What they're measuring

Number of cells

Timeframe: Baseline

Number of cells

Timeframe: 48 hours after last chest pain episode

Number of cells

Timeframe: 1 month visit

Trial details

NCT IDNCT02244710

SponsorFundación Investigación Sanitaria en León

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-09

View on ClinicalTrials.gov More Acute Coronary Syndrome (ACS) trials